Hybrid deep model for predicting anti-cancer drug efficacy in colorectal cancer patients

被引:0
|
作者
Karthikeyan, A. [1 ]
Jothilakshmi, S. [1 ]
Suthir, S. [2 ]
机构
[1] Annamalai Univ, Dept Informat Technol, Chidambaram 608002, Tamil Nadu, India
[2] Amrita Vishwa Vidyapeetham, Dept Comp Sci & Engn, Amrita Sch Comp, Chennai, Tamil Nadu, India
关键词
Drug efficacy prediction; Recursive Feature Elimination with Hybrid Machine Learning mechanism; Gini impurity; Updated Rectified Linear Unit-Deep Convolutional Neural Network; Colorectal Cancer;
D O I
10.3233/WEB-230260
中图分类号
TP18 [人工智能理论];
学科分类号
081104 ; 0812 ; 0835 ; 1405 ;
摘要
Cancers are genetically diversified, so anticancer treatments have different levels of efficacy on people due to genetic differences. The main objective of this work is to predict the anticancer drug efficiency for colorectal cancer patients to reduce the mortality rates and provides immune energy for the patients. This paper proposes a novel anti-cancer drug efficacy system in colorectal cancer patients. The input data gene is normalized with the Min-Max normalization technique that normalizes the data in distinct scales. Subsequently, proposes an improved entropy-based feature to evaluate the uncertainty distribution of data, in which it induces weight to overcome the issue of computational complexity. Along with this feature, a correlation-based feature and statistical features are also retrieved. Subsequently, proposes a Recursive Feature Elimination with Hybrid Machine Learning (RFEHML) mechanism for selecting the appropriate feature set by eliminating the recursive features with the aid of hybrid Machine Learning strategies that combine decision tree and logistic regression. Also, the Gini impurity is employed for ranking the feature and selecting the maximum importance score by eliminating the least acquired importance score. Further, proposes a hybrid model for predicting the drug efficiency with the trained feature set. The hybrid model comprises of Long Short-Term Memory (LSTM) and Updated Rectified Linear Unit-Deep Convolutional Neural Network (UReLU-DCNN) model, in which DCNN is modified by updating the activation function at the fully connected layer. Consequently, the learned feature predicts the drug efficacy of anti-cancer in colorectal cancer patients by determining whether the patient is a responder or non- responder of the drug. Finally, the performance of the proposed RFEHML model is compared with other traditional approaches. It is found that the developed method has higher accuracy for each learning percentage, with values of 60LP = 92.48%, 70LP = 94.28%, 80LP = 95.24%, and 90LP = 96.86%, respectively.
引用
收藏
页码:359 / 380
页数:22
相关论文
共 50 条
  • [41] Loading of Gemcitabine on chitosan magnetic nanoparticles increases the anti-cancer efficacy of the drug
    Parsian, Maryam
    Unsoy, Gozde
    Mutlu, Pelin
    Yalcin, Serap
    Tezcaner, Aysen
    Gunduz, Ufuk
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2016, 784 : 121 - 128
  • [42] A Microvascularized Tumor-mimetic Platform for Assessing Anti-cancer Drug Efficacy
    Shantanu Pradhan
    Ashley M. Smith
    Charles J. Garson
    Iman Hassani
    Wen J. Seeto
    Kapil Pant
    Robert D. Arnold
    Balabhaskar Prabhakarpandian
    Elizabeth A. Lipke
    Scientific Reports, 8
  • [43] Accumulation of liposomes in metastatic tumor sites is not necessary for anti-cancer drug efficacy
    Kalra, Jessica
    Baker, Jennifer
    Sun, Xuxin
    Kyle, Alastair
    Minchinton, Andrew
    Bally, Marcel B.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [44] MOOMIN: Deep Molecular Omics Network for Anti-Cancer Drug Combination Therapy
    Rozemberczki, Benedek
    Gogleva, Anna
    Nilsson, Sebastian
    Edwards, Gavin
    Nikolov, Andriy
    Papa, Eliseo
    PROCEEDINGS OF THE 31ST ACM INTERNATIONAL CONFERENCE ON INFORMATION AND KNOWLEDGE MANAGEMENT, CIKM 2022, 2022, : 3472 - 3483
  • [45] A Microvascularized Tumor-mimetic Platform for Assessing Anti-cancer Drug Efficacy
    Pradhan, Shantanu
    Smith, Ashley M.
    Garson, Charles J.
    Hassani, Iman
    Seeto, Wen J.
    Pant, Kapil
    Arnold, Robert D.
    Prabhakarpandian, Balabhaskar
    Lipke, Elizabeth A.
    SCIENTIFIC REPORTS, 2018, 8
  • [46] Anti-cancer efficacy of biotinylated chitosan nanoparticles in liver cancer
    Cheng, Mingrong
    Zhu, Weiping
    Li, Qing
    Dai, Dejian
    Hou, Yiming
    ONCOTARGET, 2017, 8 (35) : 59068 - 59085
  • [47] Pharmacokinetic/pharmacodynamic model of a methionine starvation based anti-cancer drug
    N. Eymard
    N. Bessonov
    V. Volpert
    P. Kurbatova
    F. Gueyffier
    P. Nony
    Medical & Biological Engineering & Computing, 2023, 61 (7) : 1697 - 1722
  • [48] Pharmacokinetic/pharmacodynamic model of a methionine starvation based anti-cancer drug
    Eymard, N.
    Bessonov, N.
    Volpert, V.
    Kurbatova, P.
    Gueyffier, F.
    Nony, P.
    MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING, 2023, 61 (07) : 1697 - 1722
  • [49] LIMITING THE DEVELOPMENT OF ANTI-CANCER DRUG RESISTANCE IN A SPATIAL MODEL OF MICROMETASTASES
    Shah, Ami B.
    Rejniak, Katarzyna A.
    Gevertz, Jana L.
    MATHEMATICAL BIOSCIENCES AND ENGINEERING, 2016, 13 (06) : 1185 - 1206
  • [50] METFORMIN - FROM ANTI-DIABETIC DRUG TO ANTI-CANCER DRUG
    Markowicz-Piasecka, Magdalena
    Huttunen, Kristiina M.
    Mikiciuk-Olasik, Elzbieta
    Mateusiak, Lukasz
    Sikora, Joanna
    ACTA POLONIAE PHARMACEUTICA, 2018, 75 (01): : 3 - 18